Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Substituted pyrazino[2,2-a]isoquinoline derivatives
May 25, 2017 - N°20170145010

The present invention relates to compounds of formula of formula i wherein r, r2and l are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
NEW Substituted azetidine derivatives
May 25, 2017 - N°20170144994

The present invention relates to compounds of formula of formula i wherein r, r1. R2, r2′, r3, r4, r5, l1, l2 and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
NEW Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring ...
May 25, 2017 - N°20170143959

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives
Hoffmann-la Roche Inc.
May 18, 2017 - N°20170137435

The present invention relates to compounds of formula of formula i wherein x, l and r1 are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives
Hoffmann-la Roche Inc.
May 18, 2017 - N°20170137416

The present invention relates to compounds taar receptor antagonists of formula i wherein x, r, l, ar and r1 are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin a for the treatment of neuropsychiatric and ...
Hoffmann-la Roche Inc.
May 18, 2017 - N°20170135984

Methods of treating neuropsychiatric disorders including affective disorders and addiction involve intranasal or transdermal administration of a substantially selective kappa-opioid-receptor agonist that is also a partial d2 agonist, such as the compound salvinorin a. Also disclosed are intranasal, transdermal and/or inhalation systems for delivering the kappa-opioid-receptor agonist.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor ...
Vanderbilt University
May 11, 2017 - N°20170129889

In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using ...
Trpm8 antagonists
Vanderbilt University
May 11, 2017 - N°20170129881

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
Pattern analysis based on fmri data collected while subjects perform working memory tasks allowing high-precision ...
Northwestern University
May 04, 2017 - N°20170123028

Using a plurality of distinct behavioral tasks conducted in a functional magnetic resonance imaging (fmri) scanner, fmri data acquired from one or more subjects performing working memory tasks can be used for diagnosing psychiatrics and neurological disorders. A classification algorithm can be used to determine a classification model, tune the model, and apply the model. An output indicative of a ...
Orexin receptor antagonists
Northwestern University
May 04, 2017 - N°20170121320

Wherein w, x and y1, y2, y3 and y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
System and method for diagnosis and treatment of neuropsychiatric disorders
The Research Foundation For Mental Hygiene, Inc.
April 27, 2017 - N°20170114410

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered ...
Substituted prolines / piperidines as orexin receptor antagonists
Eolas Therapeutics, Inc.
April 13, 2017 - N°20170101410

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. ...
Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases
Eolas Therapeutics, Inc.
April 13, 2017 - N°20170100389

Tetrahydroprotoberbine (thpb) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-thpbs of general formula (i). Enantioselective processes for preparing compounds of formula (i), and d- and l-govadine are also provided.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Engineered light-activated anion channel proteins and methods of use thereof
The Board Of Trustees Of The Leland Stanford Junior University
April 06, 2017 - N°20170095556

Aspects of the disclosure include compositions, devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering light-responsive polypeptides, or nucleic acids encoding same, to target cells. The subject compositions and systems include light-activated polypeptides, nucleic acids comprising nucleotide sequences encoding these polypeptides, as well ...
Peptides as oxytocin agonists
Hoffmann-la Roche Inc.
March 23, 2017 - N°20170081369

The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.
Peptides as oxytocin agonists
Hoffmann-la Roche Inc.
March 23, 2017 - N°20170081368

The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.
Pde9 inhibitors with imidazo triazinone backbone
H. Lundbeck A/s
March 23, 2017 - N°20170081333

This invention is directed to compounds, which are pde9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (i). The present invention further provides a method of treating a subject suffering ...
Serotonin receptor-targeting compounds and methods
Northeastern University
March 23, 2017 - N°20170081273

This invention relates to, in part, compositions and methods that are useful for, inter alia, the treatment of various diseases, including those linked to binding at a serotonin receptor. The compositions include chiral tetrahydronaphthalen-2-amine derivatives. Accordingly, the present invention provides for compositions and methods that agonize or antagonize one or more serotonin receptors and which find use in the ...
Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
Centre For Addiction And Mental Health
March 16, 2017 - N°20170073755

The invention provides methods and compositions for the treatment of a subject having a psychiatric disease or dis order based upon the subject's genotype and/or the number of risk alleles carried by the subject, which risk alleles have been found by the present inventors to predispose a subject to antipsychotic medication induced weight gain (aiwg). The methods of the ...
Suprametallogels and uses thereof
Massachusetts Institute Of Technology
March 16, 2017 - N°20170073311

The disclosure provides nanostructures (e. G., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e. G., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y. The provided supramolecular complexes are able to form gels (e. G., hydrogels). The ...
Magnetic stimulation methods and devices for therapeutic treatments
Btl Holdings Limited
March 16, 2017 - N°20170072212

Methods and devices producing time varying magnetic field have therapeutic uses. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch. The coil is flexibly attached in a case. The device has at least one blower for cooling the coil. The methods and devices can be used in for example in ...